Tian Li1, Rui Providencia2, Wenhua Jiang1, Manling Liu1, Lu Yu3, Chunhu Gu4, Alex Chia Yu Chang5, Heng Ma6. 1. Department of Physiology and Pathophysiology, Fourth Military Medical University, No. 169 Changle West Rd, Xi'an, 710032, China. 2. Barts Heart Centre, St. Bartholomew's Hospital, London, UK. 3. Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. 4. Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. 5. Department of Cardiology and Shanghai Institute of Precision Medicine, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 211125, China. alexchang@shsmu.edu.cn. 6. Department of Physiology and Pathophysiology, Fourth Military Medical University, No. 169 Changle West Rd, Xi'an, 710032, China. hengma@fmmu.edu.cn.
Abstract
INTRODUCTION: Whether metformin reduces all-cause cardiovascular mortality and the incidence of cardiovascular events in patients with pre-existing cardiovascular diseases (CVD) remains inconclusive. Some randomised controlled trials (RCTs) and cohort studies have shown that metformin is associated with an increased risk of mortality and cardiovascular events. METHODS: We conducted a pooling synthesis to assess the effects of metformin in all-cause cardiovascular mortality and incidence of cardiovascular events in patients with CVD. Studies published up to October 2021 in PubMed or Embase with a registration in PROSPERO (CRD42020189905) were collected. Both RCT and cohort studies were included. Hazard ratios (HR) with 95% CI were pooled across various trials using the random-effects model. RESULTS: This study enrolled 35 published studies (in 14 publications) for qualitative synthesis and identified 33 studies (published in 26 publications) for quantitative analysis. We analysed a total of 61,704 patients, among them 58,271 patients were used to calculate all-cause mortality while 12,814 patients were used to calculate cardiovascular mortality. Compared with non-metformin control, metformin usage is associated with a reduction in all-cause mortality (HR: 0.90; 95% CI 0.83, 0.98; p = 0.01), cardiovascular mortality (HR: 0.89; 95% CI 0.85, 0.94; p < 0.0001), incidence of coronary revascularisation (HR: 0.79; 95% CI 0.64, 0.98; p = 0.03), and heart failure (HR: 0.90; 95% CI 0.87, 0.94; p < 0.0001) in patients with pre-existing cardiovascular diseases. CONCLUSION: Metformin use is associated with a reduction in all-cause mortality, cardiovascular mortality, incidence of coronary revascularisation, and heart failure in patients with CVD; however, metformin usage was not associated with reduction in the incidence of myocardial infarction, angina, or stroke.
INTRODUCTION: Whether metformin reduces all-cause cardiovascular mortality and the incidence of cardiovascular events in patients with pre-existing cardiovascular diseases (CVD) remains inconclusive. Some randomised controlled trials (RCTs) and cohort studies have shown that metformin is associated with an increased risk of mortality and cardiovascular events. METHODS: We conducted a pooling synthesis to assess the effects of metformin in all-cause cardiovascular mortality and incidence of cardiovascular events in patients with CVD. Studies published up to October 2021 in PubMed or Embase with a registration in PROSPERO (CRD42020189905) were collected. Both RCT and cohort studies were included. Hazard ratios (HR) with 95% CI were pooled across various trials using the random-effects model. RESULTS: This study enrolled 35 published studies (in 14 publications) for qualitative synthesis and identified 33 studies (published in 26 publications) for quantitative analysis. We analysed a total of 61,704 patients, among them 58,271 patients were used to calculate all-cause mortality while 12,814 patients were used to calculate cardiovascular mortality. Compared with non-metformin control, metformin usage is associated with a reduction in all-cause mortality (HR: 0.90; 95% CI 0.83, 0.98; p = 0.01), cardiovascular mortality (HR: 0.89; 95% CI 0.85, 0.94; p < 0.0001), incidence of coronary revascularisation (HR: 0.79; 95% CI 0.64, 0.98; p = 0.03), and heart failure (HR: 0.90; 95% CI 0.87, 0.94; p < 0.0001) in patients with pre-existing cardiovascular diseases. CONCLUSION: Metformin use is associated with a reduction in all-cause mortality, cardiovascular mortality, incidence of coronary revascularisation, and heart failure in patients with CVD; however, metformin usage was not associated with reduction in the incidence of myocardial infarction, angina, or stroke.
Authors: Laura P Westphal; Roni Widmer; Ulrike Held; Klaus Steigmiller; Christian Hametner; Peter Ringleb; Sami Curtze; Nicolas Martinez-Majander; Marjaana Tiainen; Christian H Nolte; Jan F Scheitz; Hebun Erdur; Alexandros A Polymeris; Christopher Traenka; Ashraf Eskandari; Patrik Michel; Mirjam R Heldner; Marcel Arnold; Andrea Zini; Laura Vandelli; Jonathan M Coutinho; Adrien E Groot; Visnja Padjen; Dejana R Jovanovic; Yannick Bejot; Céline Brenière; Guillaume Turc; Pierre Seners; Alessandro Pezzini; Mauro Magoni; Didier Leys; Sixtine Gilliot; Michael J Scherrer; Georg Kägi; Andreas R Luft; Henrik Gensicke; Paul Nederkoorn; Turgut Tatlisumak; Stefan T Engelter; Susanne Wegener Journal: Neurology Date: 2020-06-29 Impact factor: 9.910
Authors: Konstantinos A Toulis; Krishnarajah Nirantharakumar; Chrysa Pourzitaki; Anthony H Barnett; Abd A Tahrani Journal: Drugs Date: 2020-04 Impact factor: 9.546
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: M G Wulffelé; A Kooy; P Lehert; D Bets; J C Ogterop; B Borger van der Burg; A J M Donker; C D A Stehouwer Journal: J Intern Med Date: 2003-11 Impact factor: 8.989